MRK earnings analysis
What we found in MRK's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Merck delivered $16.607 billion of second-quarter revenue, up 1.9% sequentially and 5.0% year over year, and above the $16.388 billion consensus estimate. EPS was a $0.13 loss, improving from the prior quarter’s $1.72 loss but missing the $0.23 estimate and remaining well below the $1.76 year-ago result. The FY2026 sales outlook was raised to $66.3 billion-$67.3 billion, but EPS guidance was reduced to $2.66-$2.76 because of Terns-related acquisition charges. The filing text provided does not include quantitative segment, balance-sheet, cash-flow, or current-quarter margin detail.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew sequentially and year over year
- Second-quarter revenue was $16.607 billion, up approximately 1.9% from $16.29 billion in the first quarter and 5.0% from $15.81 billion in the year-ago quarter. Revenue also exceeded the $16.388 billion consensus estimate by approximately $219 million.
- EPS improved sequentially but missed consensus
- Reported EPS was a loss of $0.13, an improvement from the prior quarter’s loss of $1.72 but sharply below $1.76 in the year-ago quarter and the $0.23 consensus estimate.
- FY2026 sales outlook was raised
- Management raised and narrowed FY2026 sales expectations to $66.3 billion-$67.3 billion from $65.8 billion-$67.0 billion, indicating greater confidence in the revenue trajectory.
- Share repurchases continued
- Merck repurchased 6,101,427 shares during the quarter at an average price of $116.55, with $5.736 billion remaining under the buyback authorization at June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Terns charges materially reduced EPS outlook
- Non-GAAP FY2026 EPS guidance was cut to $2.66-$2.76 from $5.04-$5.16, a reduction of $2.38-$2.40 per share, principally because of Terns-related acquisition charges.
- Margin volatility remains elevated
- Gross margin declined to 66.2% in the immediately preceding quarter from 74.2% in the first quarter, while operating margin moved from negative 20.9% to 23.5%; the filing data indicate significant margin volatility associated with charges and mix.
- No material market-risk update disclosed
- The company states that there were no material changes in market-risk exposures versus the 2025 Form 10-K, but cautions that actual results may differ materially from forward-looking statements because of known and unknown risks and uncertainties.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.13
What they said about what is next.
The quantitative outlook was mixed: FY2026 sales guidance was raised and narrowed to $66.3 billion-$67.3 billion from $65.8 billion-$67.0 billion, while non-GAAP EPS guidance was lowered to $2.66-$2.76 from $5.04-$5.16, principally due to Terns-related acquisition charges. No additional quantitative outlook was identified in the 10-Q text provided.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 4, 2026
- For Q1 2026, Merck reported revenues of $16.29 billion, reflecting a 5% increase year-over-year, outpacing estimates. However, the company posted a GAAP loss per share of $1.72, which was worse than expected, leading to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MRK makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever